ISIS-SMNRx: Phase Ib/IIa started

Isis began an open-label, dose-escalation, U.S. Phase Ib/IIa trial to evaluate intrathecal injections of ISIS-SMNRx in about 24 patients ages 2-15 years. In January, Isis granted Biogen Idec an exclus...